These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 20304062)

  • 21. In vitro and in vivo effects of vitamin D (calcitriol) administration on the normal neonatal and prepubertal prostate.
    Konety BR; Leman E; Vietmeier B; Arlotti J; Dhir R; Getzenberg RH
    J Urol; 2000 Nov; 164(5):1812-8. PubMed ID: 11025775
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anthocyanin extracted from black soybean reduces prostate weight and promotes apoptosis in the prostatic hyperplasia-induced rat model.
    Jang H; Ha US; Kim SJ; Yoon BI; Han DS; Yuk SM; Kim SW
    J Agric Food Chem; 2010 Dec; 58(24):12686-91. PubMed ID: 21121678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel nonsecosteroidal vitamin D receptor modulator inhibits the growth of LNCaP xenograft tumors in athymic mice without increased serum calcium.
    Polek TC; Murthy S; Blutt SE; Boehm MF; Zou A; Weigel NL; Allegretto EA
    Prostate; 2001 Nov; 49(3):224-33. PubMed ID: 11746268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia.
    Kojima Y; Sasaki S; Oda N; Koshimizu TA; Hayashi Y; Kiniwa M; Tsujimoto G; Kohri K
    Prostate; 2009 Oct; 69(14):1521-8. PubMed ID: 19544328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Homologous up-regulation of vitamin D receptors is tissue specific in the rat.
    Gensure RC; Antrobus SD; Fox J; Okwueze M; Talton SY; Walters MR
    J Bone Miner Res; 1998 Mar; 13(3):454-63. PubMed ID: 9525346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgen and prostatic stroma.
    Niu YJ; Ma TX; Zhang J; Xu Y; Han RF; Sun G
    Asian J Androl; 2003 Mar; 5(1):19-26. PubMed ID: 12646998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between prostatic atrophy and apoptosis in the canine spontaneous benign prostatic hyperplasia (BPH) following chlormadinone acetate (CMA).
    Murakoshi M; Ikeda R; Fukui N; Nakayama T
    Tokai J Exp Clin Med; 2001 Jul; 26(2):71-5. PubMed ID: 11806444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oral exposure to low-dose bisphenol A aggravates testosterone-induced benign hyperplasia prostate in rats.
    Wu JH; Jiang XR; Liu GM; Liu XY; He GL; Sun ZY
    Toxicol Ind Health; 2011 Oct; 27(9):810-9. PubMed ID: 21415097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
    Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
    Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of D-004, a lipid extract from Cuban royal palm fruit, on histological changes of prostate hyperplasia induced with testosterone in rats.
    Noa M; Arruzazabala ML; Carbajal D; Más R; Molina V
    Int J Tissue React; 2005; 27(4):203-11. PubMed ID: 16440586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and experimental studies of benign prostatic hyperplasia.
    Coffey DS; Walsh PC
    Urol Clin North Am; 1990 Aug; 17(3):461-75. PubMed ID: 1695775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mepartricin long-term administration regulates steroid hormone and adrenergic receptor concentrations in the prostate of aged rats.
    Barbero R; Badino P; Odore R; Galmozzi MR; Cuniberti B; Zanatta R; Re G
    J Vet Pharmacol Ther; 2006 Aug; 29(4):289-97. PubMed ID: 16846466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Establishment of prostatic hyperplasia model with castration beagle canines].
    Wu JH; Sun ZY; Zhu Y; Zhong EH; He GL; Liu GM
    Zhonghua Nan Ke Xue; 2003 Sep; 9(6):425-8. PubMed ID: 14574805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vitamin C supplementation prevents testosterone-induced hyperplasia of rat prostate by down-regulating HIF-1alpha.
    Li SH; Ryu JH; Park SE; Cho YS; Park JW; Lee WJ; Chun YS
    J Nutr Biochem; 2010 Sep; 21(9):801-8. PubMed ID: 19716283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder.
    Morelli A; Vignozzi L; Filippi S; Vannelli GB; Ambrosini S; Mancina R; Crescioli C; Donati S; Fibbi B; Colli E; Adorini L; Maggi M
    Prostate; 2007 Feb; 67(3):234-47. PubMed ID: 17163492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 1 alpha,25-Dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer.
    Nakagawa K; Kawaura A; Kato S; Takeda E; Okano T
    Carcinogenesis; 2005 Feb; 26(2):429-40. PubMed ID: 15539405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-activity relationship of nonsecosteroidal vitamin D receptor modulators.
    Yamada S; Makishima M
    Trends Pharmacol Sci; 2014 Jul; 35(7):324-37. PubMed ID: 24865943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunolocalization of androgen receptor in canine prostatic hyperplasia--effect of antiandrogen.
    Murakoshi M; Ikeda R; Tagawa M; Nakayama T; Honma S; Mieda M
    Tokai J Exp Clin Med; 1998 Nov; 23(5):209-12. PubMed ID: 10418722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent role of inflammation in prostate diseases: chemoprevention development opportunity.
    Hamid AR; Umbas R; Mochtar CA
    Acta Med Indones; 2011 Jan; 43(1):59-65. PubMed ID: 21339547
    [TBL] [Abstract][Full Text] [Related]  

  • 40. α-Spinasterol from Melandrium firmum attenuates benign prostatic hyperplasia in a rat model.
    Lee MY; Shin IS; Kyoung H; Seo CS; Son JK; Shin HK
    Mol Med Rep; 2014 Jun; 9(6):2362-6. PubMed ID: 24682042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.